The traditional healthcare delivery model is changing
Payment models and federal reforms are increasingly focused on the real world impact of treatments and devices. Learn how real world evidence is helping to close the evidence gap between traditional clinical trials and the broader patient population.
Get insights on the key contracting issues you should be considering today to optimise the commercial success of your products
As industry shifts from a fee-for-service healthcare delivery model to one with a greater focus on the value a treatment brings to patient health and system outcomes, drug and medical device developers are taking a more integrated approach in developing their product’s regulatory and reimbursement strategies.
ICON is leading the way to support pharma, biotech and medical device clients through its dedicated Value Access and Outcomes experts, who apply state-of-the-art technology, advanced methodologies and deep expertise to identify, generate, synthesise and communicate meaningful evidence of their treatments’ value.
Understanding and meeting the evidence requirements of regulators and HTA bodies can be complex. Early engagement can help. Read the whitepaper for key factors to ensure that parallel consultation meetings are well prepared, productive and informative.Read the whitepaper
In the absence of a national HTA body in the US, ICER has emerged as a leading voice in evaluating healthcare technologies on their clinical and economic value. Read our third annual payer survey for insights.Read the whitepaper
In the US, payers have historically focused on efficacy and safety endpoints as well as cost, with very little attention given to patient reported outcomes (PROs). With the increase in patient centricity, we surveyed US payers from MCOs, IDNs and PBMs to get their take on the value and use of PRO data.Read the whitepaper
How will the changes brought about by the pandemic impact your existing pipeline of products? Will you need to adjust your existing HEOR evidence planning and timetables? Are there steps you can take to ensure that patients and providers will still have timely access to your pipeline of products?Read the whitepaper
Digital health innovations can help people better manage chronic diseases and access healthcare when they need it, improving adherence to medications and preventing complications. Our whitepaper provides an introduction and review of digital health and the current regulatory landscape, with a focus on how various US payers perceive these new innovations. Our original research uncovers how US payer organizations currently evaluate and manage digital therapeutics, and their perspectives for the future.Read the whitepaper
Payer Reliance on ICER Assessments and Perceptions on Value-based Pricing
In 2019, the Institute for Clinical and Economic Review (ICER) launched an international collaboration to develop new methods to guide value-based pricing. This initiative led us to conduct original research on payer reliance on ICER assessments and their perceptions on value-based pricing over the past year, as an update to our original 2018 research.
Read the whitepaper
ICER as an independent HTA organisation: Industry perception & expectations
In 2018, we conducted primary research to evaluate the influence of the Institute for Clinical and Economic Review (ICER) over payers and manufacturer, and analysis on the potential savings to the US healthcare system.
Read our whitepaper, The role of ICER as an independant HTA organisation
Forbes article: ICER's growing impact on drug pricing and reimbursement
Discover the key regulatory and development concerns for sponsors, including the factors that affect biosimilar uptake in the United States and Europe and recommendations to address these issues.Read the whitepaper
Learn how this hybrid approach to study design can be advantageous for generating real world evidence. Get insights on the issues you need to consider to ensure that your study is planned to produce robust scientific data that can be extrapolated beyond the study population.Read the whitepaper
If you would like to receive our Value Based Healthcare development email updates, including the latest on commercialisation & outcomes, pricing & market access, real world evidence, as well as regulatory updates, click here to go to our preference centre.Receive Value Based Healthcare email updates
ICON and ICHOM unveiled the world’s first global patient outcomes benchmarking platform, enabling the collection, storage, aggregation, analysis and visualisation of health outcomes data, at the 2017 ICHOM annual conference.
Through its relationship with ICON, ICHOM is creating a secure central platform where outcomes data is compiled from participating provider organisations around the world. This will enable provider organisations to compare the health outcomes of their patients to those of their peers.
As healthcare systems shift towards value based health care payment models, device developers will need to adopt a strategic approach to maintain premium pricing on the market and to bring new high-value products to market. To be successful, device developers will need an understanding of how incentives are structured and how they influence varying stakeholder interests and behaviours. In addition, they have to identify stakeholder needs early and create strategies for developing evidence to make a compelling value based case for target stakeholder groups.
Read our white paper to learn more about our model for mapping stakeholder value that can help drive profitable device development programmes in increasingly value driven markets.
The precision medicine strategies discussed in this paper present a range of opportunities for new drugs and devices targeted to specific patient populations. These technologies work synergistically together, creating greater value during development and in the clinic. The future will continue to bring rapid convergence of the pharmaceutical and device industries, driven together by the patient, payer, and regulatory forces that are currently shaping the precision medicine market. As we look forward, the future patient may even create a new relationship with device manufacturers as a partner in personalising his or her own healthcare and clinical trial experiences.Download whitepaper
In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US.
How can medical device manufacturers sustain growth and successfully navigate this new model? Download our white paper, Thriving in Value-Based Healthcare: A guide for cardiovascular device manufacturers
Gain insights to best practices for developing a comprehensive health economic and epidemiologic evidence strategy and evidence generation plan that is targeted to meet the needs of regulators and payers.
The demand from regulators and payers for health economic models is increasing, as these key decision makers struggle to manage budget constraints and provide access to new therapies.
If you would like to receive our Value Based Healthcare development email updates, including the latest on commercialisation & outcomes, pricing & market access, real world evidence, as well as regulatory updates, click here to go to our preference centre.Receive Value Based Healthcare Email Updates
The following briefing is drawn from our webinar ‘Using Early Economic Models in Developing Your Evidence Strategy,’ and explains the nature and value of these models and presents guidelines for their development.